Anti-inflammatory effect of the antidepressant fluvoxamine – a systematic review

• Autor(a) principal: Ramalho, A.
• Data de Publicação: 2022
• Outros Autores: Carvalho, R., Barroso, F., Cruz, A., Santos, M.
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: http://hdl.handle.net/10400.22/21696

Neuroinflammation corresponds to the immune response of the nervous system to an injury, infection or neurodegenerative disease characterized by the activation of resident glial cells, including microglia and astrocytes, the release of cytokines and chemokines and the activation and migration of leukocytes. Evidence suggests that inflammatory cytokines may be a central factor, affecting multiple neuronal pathways and contributing to the development of depression. Supporting this neuroinflammatory theory, several studies have demonstrated the anti-inflammatory effect of various antidepressant drugs [1]. Fluvoxamine is a selective serotonin uptake inhibitor (SSRIs) used manly in the treatment of depression and anxiety disorders. Recent evidence pointed that a fluvoxamine early treatment on SARS-CoV-2-infected subjets fully prevented COVID-19 symptoms [2]. Thus, it seems relevant to explore the anti-inflammatory mechanism of fluvoxamine.